Real-World Experience With Control-IQ Technology in Saudi Children With Insulin-Dependent Diabetes: A Single-Center Observational Study.

IF 1.9 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Pediatric Diabetes Pub Date : 2026-03-01 eCollection Date: 2026-01-01 DOI:10.1155/pedi/6113065

Afaf Alsagheir, Bassam Bin-Abbas, Razan Alsagheir, Raghad Alhuthil, Aseel Aljuwair, Norah H Alobailly, Sheikhah Almoaily

{"title":"Real-World Experience With Control-IQ Technology in Saudi Children With Insulin-Dependent Diabetes: A Single-Center Observational Study.","authors":"Afaf Alsagheir, Bassam Bin-Abbas, Razan Alsagheir, Raghad Alhuthil, Aseel Aljuwair, Norah H Alobailly, Sheikhah Almoaily","doi":"10.1155/pedi/6113065","DOIUrl":null,"url":null,"abstract":"Objectives: The Tandem t:slim X2 insulin pump with the Control-IQ technology (Control-IQ) is an automated insulin delivery (AID) system for glycemic control but has limited data in Saudi pediatric and young adult populations. We aim to evaluate the efficacy and safety of Control-IQ therapy in children with insulin-dependent diabetes and previously treated with multiple daily injections (MDIs). The primary outcome is to assess the change in HbA1c 6 months after initiating Control-IQ technology.Methods: This prospective observational study evaluated children aged 2-14 years with insulin-dependent diabetes who transitioned from treatment with MDI to the Control-IQ technology in the diabetes clinic at the King Faisal Specialist Hospital and Research Centre (KFSHRC) in Saudi Arabia.Results: A total of 100 patients (44 boys and 56 girls; median age was 11 years) were included. Most (82%) had a history of severe hypoglycemia. Following Control-IQ initiation, median HbA1c significantly decreased from 9.2% to 6.9% at 6 months (-25.0%; p < 0.001), accompanied by a 24.4% reduction in the daily insulin dose. Time in range (TIR) (70-180 mg/dL) improved from 45.6% to 68.8% (+23.2%; p < 0.001), while time in significant hypoglycemia (<54 mg/dL) decreased by 88.9% (p < 0.001). At 6 months, 83% achieved ≥60% TIR, and 54% reached ≥70%. Adherence and engagement were high, with no severe hypoglycemia or discontinuations. Only 3% experienced mild/moderate ketoacidosis due to technical issues in the Control-IQ.Conclusions: The findings demonstrated that Control-IQ technology is both effective and safe in improving glycemic outcomes in children with insulin-dependent diabetes in a real-world clinical setting. However, successful implementation requires comprehensive training and continuous support.","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2026 ","pages":"6113065"},"PeriodicalIF":1.9000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12950901/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/pedi/6113065","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The Tandem t:slim X2 insulin pump with the Control-IQ technology (Control-IQ) is an automated insulin delivery (AID) system for glycemic control but has limited data in Saudi pediatric and young adult populations. We aim to evaluate the efficacy and safety of Control-IQ therapy in children with insulin-dependent diabetes and previously treated with multiple daily injections (MDIs). The primary outcome is to assess the change in HbA1c 6 months after initiating Control-IQ technology.

Methods: This prospective observational study evaluated children aged 2-14 years with insulin-dependent diabetes who transitioned from treatment with MDI to the Control-IQ technology in the diabetes clinic at the King Faisal Specialist Hospital and Research Centre (KFSHRC) in Saudi Arabia.

Results: A total of 100 patients (44 boys and 56 girls; median age was 11 years) were included. Most (82%) had a history of severe hypoglycemia. Following Control-IQ initiation, median HbA1c significantly decreased from 9.2% to 6.9% at 6 months (-25.0%; p < 0.001), accompanied by a 24.4% reduction in the daily insulin dose. Time in range (TIR) (70-180 mg/dL) improved from 45.6% to 68.8% (+23.2%; p < 0.001), while time in significant hypoglycemia (<54 mg/dL) decreased by 88.9% (p < 0.001). At 6 months, 83% achieved ≥60% TIR, and 54% reached ≥70%. Adherence and engagement were high, with no severe hypoglycemia or discontinuations. Only 3% experienced mild/moderate ketoacidosis due to technical issues in the Control-IQ.

Conclusions: The findings demonstrated that Control-IQ technology is both effective and safe in improving glycemic outcomes in children with insulin-dependent diabetes in a real-world clinical setting. However, successful implementation requires comprehensive training and continuous support.

查看原文本刊更多论文

控制智商技术在沙特胰岛素依赖型糖尿病儿童中的实际应用：一项单中心观察研究。

目的：采用control - iq技术（control - iq）的Tandem t:slim X2胰岛素泵是一种用于血糖控制的自动胰岛素输送（AID）系统，但在沙特儿童和年轻成人人群中的数据有限。我们的目的是评估Control-IQ疗法对胰岛素依赖型糖尿病儿童的疗效和安全性，这些儿童之前接受过多次每日注射（mdi）治疗。主要结局是评估采用Control-IQ技术6个月后HbA1c的变化。方法：这项前瞻性观察性研究评估了沙特阿拉伯费萨尔国王专科医院和研究中心（KFSHRC）糖尿病诊所从MDI治疗过渡到Control-IQ技术治疗的2-14岁胰岛素依赖型糖尿病儿童。结果：共纳入100例患者，其中男44例，女56例，中位年龄11岁。大多数（82%）有严重低血糖史。在Control-IQ启动后，6个月时HbA1c中位数从9.2%显著下降到6.9% (-25.0%;p < 0.001)，同时每日胰岛素剂量减少24.4%。范围内时间（TIR）（70-180 mg/dL）从45.6%改善到68.8% (+23.2%,p < 0.001)，而明显低血糖的时间（p < 0.001）。6个月时，83%达到≥60%的TIR， 54%达到≥70%。依从性和参与度高，无严重低血糖或停药。由于Control-IQ中的技术问题，只有3%的患者出现轻度/中度酮症酸中毒。结论：研究结果表明，在现实世界的临床环境中，Control-IQ技术在改善胰岛素依赖型糖尿病儿童的血糖结局方面既有效又安全。然而，成功的实施需要全面的培训和持续的支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Diabetes 医学-内分泌学与代谢

CiteScore

6.60

自引率

14.70%

发文量

141

审稿时长

4-8 weeks

期刊介绍： Pediatric Diabetes is a bi-monthly journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in childhood and adolescence. The aim of the journal is to become the leading vehicle for international dissemination of research and practice relating to diabetes in youth. Papers are considered for publication based on the rigor of scientific approach, novelty, and importance for understanding mechanisms involved in the epidemiology and etiology of this disease, especially its molecular, biochemical and physiological aspects. Work relating to the clinical presentation, course, management and outcome of diabetes, including its physical and emotional sequelae, is considered. In vitro studies using animal or human tissues, whole animal and clinical studies in humans are also considered. The journal reviews full-length papers, preliminary communications with important new information, clinical reports, and reviews of major topics. Invited editorials, commentaries, and perspectives are a regular feature. The editors, based in the USA, Europe, and Australasia, maintain regular communications to assure rapid turnaround time of submitted manuscripts.